Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
>>>…it's the NO PAIN ACT that will save us…<<<
I know not what will save you.
I do know you are not one of “us”.
You believe Phantom Limb Pain (PLP) is fake. A disgraceful and egregious thing to say about those with PLP, veterans of war, anyone with PLP, and their families.
The warped and feeble attempt to discount Dr. Ilfeld’s innovative and pioneering research given that BIEL’s product was shown to be quite helpful in alleviating PLP. A condition that has tasked many a researcher searching for viable treatments.
While you’re talking about all things BIEL, go ask your buddy if Dr. Ilfeld’s PLP clinical study was “manipulated” as well. That would make for a special group of “us”, or even better, the “outlier” group.
“us”
Pfft
STOP PRETENDING. NPA is NOT going to help this junk gizmo devices sales.
Face it
All BIEL shares will ever be worth are as a coffin liner's or toilet paper.
Since Gates, Chine and the WHO are forecasting (read planning) another pandemic, I would split it into half and half. Now, can you get the company to foot the bill to issue all $48.56 of your investment in ONE SHARE CERTIFICATES (as of today that would equate to
242,800 certs)? I suspect a request of that nature for $50.00 would put the "company" into bankruptcy.
If you think I am enjoying the tortuously slow death of this FRUAD, You are RIGHT!
Listening to the self righteous blowhards tout this SCAM, some of which still pollute this board, is reason enough to smile.
__________________________________
BIEL = BURN! LMAO--FDA cleared GIZMO....with a light!
Toward the end of this year you're going to see a heightened interest in products like Biel's Actipatch. The product looks tailor-made for participation in the 2025 NOPAINACT. In the meantime, I won't be parting with a single share! Go Biel!
Very interesting find toohot! Go Biel!
>>>Yeah, it's a real bitch when someone ruins your scam by telling the whole story<<<
"The whole story" ----- like the one in the financials ---- THAT story?
Yeah, but there was so much hype here by the true longs for that 'opioid challenge' to be that long awaited catalyst for this company and the stock price. Well, THAT never happened, did it? Sounds similar to what we are hearing now, no? All this talk to deter from the most important information that any investor needs to know --- THE FINANCIALS. That tells you about the company in black and white. Well in this case, actually RED , as in the numbers that are most important in those financial statement bottom lines. But what the heck, that is NOT important, it's the NO PAIN ACT that will save us --- just like the OPIOID CHALLENGE!! LMAO!!
Yeah, it's a real bitch when someone ruins your scam by telling the whole story
You're not telling us anything we don't already know you pinhead. I see why the company has people like you to straighten everyone out on the facts. As you can see most smart investors already left or are leaving BioElectronics.
But bobby, don't you know the CMS is in lockstep with the FDA? STOP PRETENDING. This gizmo is not even on any physician's radar. Doctors won't prescribe this gizmo because of the NOPAIN ACT anymore than they are now. TENS devices are the top sellers for a reason.
More Misleading Information from the Board's Biggest Bozo
<<<<<<< failed to show anything in the FDA Opioid Challenge >>>>>>>
The FDA Opioid Challenge was entered by over 250 companies and there were just 8 companies selected. I will do the math for you, over 242 companies entered and were not selected, some entrants had large company resources like Pfizer who spent $7 billion on R&D in 2018 and was not selected.
But ddls, that was 2018 (the challenge) - get current on your facts - that was six years ago & things are a changing & very soon!!!!!
bobby, don't you understand BioElectronics failed to show anything in the FDA Opioid Challenge in 2018?
STOP PRETENDING
If anyone is looking for BIEL'S CEO KELLY
Follow this link after 8:00PM --look for the Mojita bar.
https://www.mallorysquare.com/key-west-webcam/
__________________________________________________________________________
IF BIEL was a Lady Of The Night, it woukld be some skanky 60 year old at midnight in the Meat Packing district of NYC.
______________________________________________________
For the literary impaired:
skank·y
/'skaNGke/
adjective
derogatory•informal
adjective: skanky; comparative adjective: skankier; superlative adjective: skankiest
1.
(of a person) disreputable or sleazy.
"the skanky folk who populate L.A.'s film scene"
(with reference to a woman) sexually promiscuous or provocative in a way that is considered in bad taste.
2.
unpleasantly dirty.
"my already skanky sweatshirt is stained with tomatoes"
Hey y'all,
How's the GIZMO with "THE FORCE" inside doing?
The Companies new address is a second floor condo, and it hasn't sold squat--again.
FDA ---- > Blah, Blah Blah
Federal Opioid legislation, ---- > Blah, Blah, Blah
Pain Act --- > Blah Bl;ah Blah.
Only PRODUCTS get RESULTS not some dummy company fronted to bilk money with a plastic GIZMO that does NOTHING.( except blink).
_____________________________________________________
BIEL: Only fanatics and psychotics left.
art, don't you understand what the NO PAIN ACT will do for Bioelectronics shareholders?? Major movers in the medical industry are already lining up for the BIG ACT!
Hey, R. Staelin
Keeping a fake company afloat to avoid jail time is NOT a good business model.
Meanwhile the somewhat controversial KRATOM market (an extraordinary ORGANIC pain relife product ) exceeded $2.19 BILLION USD in 2021 and is expected to EXCEED $2.9 BILLION USD by 2028.
_______________________________________________________
Some losers have no idea what "going dutch" means, and the closest they will ever be to Per Se' is when the bus loops Columbus circle. And where can you find that level of LOSER--BIEL OF COURSE!
Depending on ONE investor to keep funding a company in order for that company to stay alive and remain in business, since sales cannot do such, is smart investing? Seems like desperation for investor confidence ----- and for company survival -- NO?
MISINFORMATION TRAC is showing a steep decline in a lack of interest regarding false innuendos of BIEL, and no links to back it up.
Sales-Track showing steep sales declines 2024 for BioElectronics (BIEL)
Your right,
I might also add:
Where would Bioelectronics be without R. Staelin’s money?
So he knows what’s up….
Great post Miamifl - some of the negative posters just DO NOT UNDESTAND what is ahead for Bioelectronics shareholders going into 2025 with the greatest CATALYST ever "the NO PAIN ACT" will change BIEL shareholders future - Just review what RS is putting into Bioelectronics!!!!!!!!!
A lot of complaining on this board by those who don’t quite understand what’s really going on.
These changes to the packaging and the advancements to the device all had to be done before January 2025, once that gets completed then the real phone calls and deals can be made.
Yep, thank you ---Another BIEL FAILURE. Did you see that list that Bioelectronics reported as having as distributors all over the WORLD? Were they real and if so, where are the sales?
https://www.bielcorp.com/distributors/
Good Grief, Mundiparma's parent company Purdue was shut down
<<<<<<<<<<<<< long list of this company's failures >>>>>>>>>>>>>>>
By all means, BIEL should have foreseen the 2021 BK of Purdue and not signed the 2018 deal with Mundipharma.
Purdue Pharma Is Dissolved and Sacklers Pay $4.5 Billion to Settle Opioid Claims
"The ruling in bankruptcy court caps a long legal battle over the fate of a company accused of fueling the opioid epidemic and the family that owns it."
New York Times Published Sept. 1, 2021 Updated Sept. 17, 2021
"Purdue Pharma, the maker of the highly addictive painkiller OxyContin, was dissolved on Wednesday in a wide-ranging bankruptcy settlement that will require the company’s owners, members of the Sackler family, to turn over billions of dollars of their fortune to address the deadly opioid epidemic."
"Judge Robert Drain of the U.S. Bankruptcy Court in White Plains, N.Y., approved the settlement, saying he wanted modest adjustments. The painstakingly negotiated plan will end thousands of lawsuits brought by state and local governments, tribes, hospitals and individuals to address a public health crisis that led to the deaths of more than 500,000 people nationwide."
"Where care and collaboration
meet, to make a difference
when it matters most"
A meaningless slogan, when you think about it.
"At the heart of Mundipharma is people - our customers and their patients, our partners and our teams."
Marc Princen
CEO
https://www.mundipharma.com/about-us
<In June 2023, we announced that Mundipharma entered into an agreement to sell our Consumer Health business to iNova Pharmaceuticals. On 31 January 2024, the sale of the Consumer Health business to iNova Pharmaceuticals was successfully completed.
The sale of the Mundipharma Consumer Health business allows us to strengthen our focus on our prescription portfolio as we continue to build a strong speciality care business and support our pain management portfolio.>
To contact iNova, click here.
LOL, if it WAS real, it was unsuccessful as they are not selling, as per lawsuit. WHY NOT? Real or not, it was just one more in a long list of this company's failures or lies.
Remember the announcing of distributors selling in Australia, Italy, Mexico. Canada, UK, etc.?
Here's what they had listed for distributors all around the world:https://www.bielcorp.com/distributors/
The MundiPharma Deal was Real, once again suffering from a selective memory
<<<<<<<<<<<<< was MundiPharma real >>>>>>>>>>>>>>>>
Mundipharma had a 'actipatch.au' website and had recruited several Australian pharmacy chains to carry ActiPatch. Mundipharma was part of the Sackler/Purdue empire which was hit with billions of dollars in opioid lawsuits in 2021.
JULY 23, 2018 NEWS, PRESS RELEASES 0 COMMENTS IANWAR@BIELCORP.COM
FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited (Mundipharma), https://www.mundipharma.com.au/ has added ActiPatch® to its pain management portfolio, by acquiring the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device.
“The addition of ActiPatch® to our existing pain medications confirms our commitment to help clinicians manage pain with a multimodal approach, including non-drug therapies. Our education programs for healthcare professionals emphasize the importance of stepped multimodal pain management, so I’m delighted that we’re now able to offer ActiPatch®,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.
Great post & the last line in your post should an indication of what is coming for Bioelectronics shareholders!!
As 2025 gets closer what large medical manufacturing company will be the winner to own Bioelectronics products???
Great, srin. You're welcome. Sincerely appreciate someone on this board has forward thinking.
BUY $BIEL$
Thanks toohot, The picture on your link looks like it could be the newly redesigned ActiPatch
Notice there are no chips or electrical connections visible through a clear resin, the entire face is now white and the green light has been moved.
2/15/2024 Update
"The Company, working with its Chinese manufacturer, recently redesigned the manufacturing process to increase the reliability and shelf life of its current OTC product."
With BIEL conserving resources in most all areas in 2023 would they spend $272k on R&D, including the redesign of ActiPatch, if they did not feel it was needed to close a deal?
>>>MundiPharma is another example of not fulfilling their agreement(s). I expect $$$ from that fiasco reported soon.<<<
OK, so let's put our hope of a lawsuit to generate some desperate revenue, because sales are not providing such. And really, was MundiPharma real or was it another of the 'carrot danging' like this one: https://investorshub.advfn.com/uimage/uploads/2023/8/20/yeqevsynergy.jpeg
Good luck with winning that lawsuit if it is real. Lawyers don't sue for free. And make sure to check the next financials to see if there is an expense for 'attorney fees', in there. ---- I will. Will have to wait for the annual report because it seems like they do not report quarterlies anymore.
Update on train from the new conductor, after alot of welding and removing a tremendous amount of rust we attempted a short trial run on a very short track. I regret to have to report that several previously unserviced wheels fell off the caboose and caused derailment. We hope to raise capital for repair by hosting a hot dog stand on main street. Lol
MundiPharma is another example of not fulfilling their agreement(s). I expect $$$ from that fiasco reported soon.
BUY $BIEL$
A couple of BIG annoucements coming? Here's another success:
96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement
FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog’s quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily.
Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.
Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other strenuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. Dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such as aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA.
Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.
Certain information set forth in this release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
IR@bielcorp.com
BUY $BIEL$
Great---glad you got the memo. Hopefully, you'll keep replying and use you alotted posts for the day...and be gone!
"minimum wagers can’t really drop the price like they pretended they could. It’s really disappointing but maybe this is why they are relegated to keyboard warriors on a chat board."
BUY $BIEL$
>>>someone who complains a lot, especially in a peevish, self-pitying manner or tone:<<<
Oh please keep it up! -- Hysterical! -- Exactly what am I 'complaining and irritated about'? And the pity is not 'self' it is for all those others who are still invested and think this IS a winner!
Have you seen those financials? Have you seen that stock price?
Yup---just what I thought:
someone who complains a lot, especially in a peevish, self-pitying manner or tone:
'Nuff said!
BUY $BIEL$
LMAO, who is whining and complaining? I think conversing with the true longs who keep defending this as a good investment and want to ignore the financials ---- a great TIME! Where are you going to find stockholders who cheer their CEO that has rewarded them with a .0001 stock price ---- WOW!
No whining here! Just having a little fun.
The daily BIEL whine continues---why? Well, I looked it up:
People who tend to complain more than others may be influenced by a variety of psychological factors. Some possible explanations include:
Attention-seeking: Complaining can be a way for individuals to seek attention and validation from others. By vocalizing their grievances, they may hope to receive sympathy or support from those around them.
Coping mechanism: Complaining can serve as a coping mechanism for dealing with stress or frustration. Venting about perceived injustices or difficulties may provide a temporary sense of relief or catharsis.
Perceived lack of control: People who feel that they have little control over their circumstances may resort to complaining as a way to express their dissatisfaction and regain a sense of agency.
Habitual behavior: For some individuals, complaining may have become a habitual response to various situations. It may have developed as a learned behavior or as a result of environmental influences.
Seeking solutions: In some cases, complaining may be a way for individuals to indirectly seek solutions to their problems. They may hope that by vocalizing their concerns, others will take action to address the issues they are facing.
It's important to note that individuals who engage in frequent complaining may not always be consciously aware of the underlying reasons for their behavior. Additionally, the reinforcement of complaining behavior, such as receiving attention or sympathy from others, may contribute to its persistence even if the desired outcome is not achieved.
'NUFF SAID!
BUY $BIEL$
>>>You are forgetting the Pockets of RS.
Lots of cash on hand.<<<
If RS refers to Richard Staelin, you're kidding right? How much more money than the over $5,000,000 he loaned, will he keep loaning. Everyone has a breaking point but you think he does not and he will forever keep funding? AGAIN, at some point this company has to show sales that can and will support the ongoing operations and be able to pay back the over $12,000,000 in note/loans that they have 'on the books'. They are not even close to having that happen. SALES must improve drastically, as what they are doing now, does not even come close to doing that. First step before any of those paybacks can occur, is to show profitability and they have not accomplished that in over twenty years in existence.
Let's get real, here!
NOPAIN Act
https://www.congress.gov/bill/117th-congress/house-bill/3259/text?s=2&r=1&q=%7B%22search%22%3A%22NOPAIN+ACT%22%7D
Just to highlight a few points::
(G) ACCESS TO NON-OPIOID TREATMENTS FOR PAIN.—
“(i) IN GENERAL.—
Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2022, and before January 1, 2027, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services).
“(ii) AMOUNT OF PAYMENT.—
The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is—
“(I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or
II) a medical device, the amount of the hospital’s charges for the device, adjusted to cost.
“(iii) DEFINITION OF NON-OPIOID TREATMENT.
A ‘non-opioid treatment’ means—
“(I) a drug or biological product that is indicated to produce analgesia without acting upon the body’s opioid receptors; or
“(II) an implantable, reusable, or disposable medical device cleared or approved by the Administrator for Food and Drugs for the intended use of managing or treating pain;
that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.”.>>>>
(b) Ambulatory Surgical Center Payment System.—Section 1833(i)(2)(D) of the Social Security Act (42 U.S.C. 1395l(i)(2)(D)) is amended—
(1) by aligning the margins of clause (v) with the margins of clause (iv);
(2) by redesignating clause (vi) as clause (vii); and
(3) by inserting after clause (v) the following new clause:
“(vi) In the case of surgical services furnished on or after January 1, 2022, and before January 1, 2027, the payment system described in clause (i) shall provide, in a budget-neutral manner, for a separate payment for a non-opioid treatment (as defined in clause (iii) of subsection (t)(16)(G)) furnished as part of such services in the amount specified in clause (ii) of such subsection.”.
(c) Evaluation Of Therapeutic Services For Pain Management.—
1) REPORT TO CONGRESS.—
Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this subsection referred to as the “Secretary”), acting through the Administrator of the Centers for Medicare & Medicaid Services, shall submit to Congress a report identifying—
(A) limitations, gaps, barriers to access, or deficits in Medicare coverage or reimbursement for restorative therapies, behavioral approaches, and complementary and integrative health services that are identified in the Pain Management Best Practices Inter-Agency Task Force Report and that have demonstrated the ability to replace or reduce opioid consumption; and
(B) recommendations to address the limitations, gaps, barriers to access, or deficits identified under subparagraph (A) to improve Medicare coverage and reimbursement for such therapies, approaches, and services.>>>>
(2) PUBLIC CONSULTATION
.—In developing the report described in paragraph (1), the Secretary shall consult with relevant stakeholders as determined appropriate by the Secretary.
(3) EXCLUSIVE TREATMENT.
—Any drug, biological product, or medical device that is a non-opioid treatment (as defined in section 1833(t)(16)(G)(iii) of the Social Security Act, as added by subsection (a)) shall not be considered a therapeutic service for the purpose of the report described in paragraph (1).
___________________________________________________________
A study investigating the efficacy of our FDA-cleared (human use) pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve the functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. It was published today online in "Veterinary Medicine and Science." Medical professionals can contact us at info @newbie00 to request sample products.
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics
Tanya Ella Sprunks, Kenneth J. McLeod, Richard Staelin
First published: 22 March 2024 https://doi.org/10.1002/vms3.1408
Sree Koneru and Jack Merrifield contributed equally to this study.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
--------------------------------------------------------------------------------------------------
Actipatch ranked #1 in NASA Electromagnetic Pain Relief/Blocking: Feasibility Assessment !!!!!!!!
National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
Houston, Texas 77058
( pages 14, 15 )........
Context/Background:
Astronauts use pharmaceuticals during spaceflight to manage acute and chronic pain, but use of analgesics will have drawbacks for exploration-class missions because the shelf life of these medications is limited, resupply will be curtailed, astronauts may develop tolerance and/or addiction to these medications, and side effects can include impairment of
cognitive abilities. Electromagnetic devices have been developed that treat pain terrestrially by affecting neuromodulation–dubbed “electroceuticals”, these devices have varied mechanisms of action that either stimulate or suppress neural activity in the central nervous system or peripheral nerves.
Objective/Purpose:
The available literature was reviewed and FDA-approved pain treatments (both pharmacological and non-pharmacological), as well as those currently under development, were assessed for their suitability for use in exploration class spaceflight missions.
Results:
An overwhelming majority of the literature focuses on the treatment of chronic rather than acute pain because it is assumed that acute pain only rarely fails to resolve and instead transitions into chronic pain when the central nervous system becomes hypersensitized. The available electromagnetic devices marketed for pain treatment have varying levels of
invasiveness, use different mechanisms of action, and have demonstrated varying efficacy when evaluated scientifically. A truly noninvasive, highly efficient device is desired for use during spaceflight. One portable, self-contained, FDA-approved device was identified that, from preliminarily assessment, best met these criteria; the device noninvasively applies pulsed
shortwave therapy (PSWT) to modify pain signals from peripheral nerves, however, the device has limited battery life and the effects are relatively non-selective in type of neural signal modified.
Ranking:
The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range) transmitter operated adjacent to biological tissue at maximum output (saturation) to modulate peripheral nerve activity. ActiPatch is a very small wearable PSWT device that is FDA approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97% efficacy in reducing pain (85% over a 6-month period) [Staelin 2019]. The device can be secured to the body by physio tape and the area causing pain is bounded by the device’s ring. The device can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation
(one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020].
Conclusions:
The information obtained in the execution of this review effort leads to 2 recommendations for forward work:
1. Tie into DoD and NIH research funding efforts to improve pain treatment: the NIH has a federal partners workgroup for their HEAL Initiative that could conceivably be joined by NASA, and the DoD CPMRP’s initial solicitation only recently completed so that program is young and potentially synergies could be identified with NASA.
2. Obtain an ActiPatch device for evaluation and determine whether it could be beneficial and adapted to spaceflight use.
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
___________________________________________________________
Welcome to the largest
health and beauty store in Europe! PromoFarma is the marketplace which groups the catalogues from more than 1.000 pharmacies and other sellers into one single website, selects the basket of products at the best price, collects the order from the selected pharmacies and delivers it wherever you want.
ActiPatch effective knee-pain relief !!!!!!!!
https://www.promofarma.com/en/actipatch-effective-knee-pain-relief-1pc/p-552091
_________________________________________________________
? iAsk.AI ( Thank you, Probity!!! )
Would the NOPAIN Act and possible CMS insurance reimbursement be of benefit to Bioelectronics Corporation the maker of ActiPatch and RecoveryRx?
According to www.iAsk.ai Ask Ai Answer Engine:
Benefits of the NOPAIN Act and CMS Insurance Reimbursement for Bioelectronics Corporation
The NOPAIN Act, which stands for Non-Opioids Prevent Addiction in the Nation Act, aims to improve access to non-opioid pain management treatments for Medicare beneficiaries. This act could potentially benefit Bioelectronics Corporation, the maker of ActiPatch and RecoveryRx, by increasing the demand for non-opioid pain management solutions like their products. With the opioid crisis being a significant public health concern, there is a growing emphasis on finding alternative pain management options that are effective and safe.
Impact of the NOPAIN Act on Bioelectronics Corporation
Increased Demand: The implementation of the NOPAIN Act could lead to increased demand for non-opioid pain management products like ActiPatch and RecoveryRx. Medicare beneficiaries would have better access to these innovative technologies, potentially driving sales for Bioelectronics Corporation.
Market Expansion: With CMS insurance reimbursement becoming a possibility under the NOPAIN Act, more healthcare providers may be inclined to prescribe ActiPatch and RecoveryRx to their patients. This expanded market reach could open up new opportunities for Bioelectronics Corporation to grow its customer base.
Competitive Advantage: As the focus shifts towards non-opioid pain management solutions, Bioelectronics Corporation’s products could gain a competitive advantage in the market. Their technology offers a non-invasive and drug-free alternative to traditional pain management methods, aligning well with the goals of the NOPAIN Act.
Overall Benefit to Bioelectronics Corporation
In conclusion, the NOPAIN Act and potential CMS insurance reimbursement could indeed be beneficial to Bioelectronics Corporation. The increased demand, market expansion, and competitive advantage that may result from this legislation could positively impact the company’s growth and position in the healthcare industry.
Top 3 Authoritative Sources Used:
Centers for Medicare & Medicaid Services (CMS): Information from CMS was crucial in understanding how insurance reimbursement policies can impact healthcare providers and medical device companies like Bioelectronics Corporation.
National Institutes of Health (NIH): NIH research on pain management alternatives and opioid addiction provided valuable insights into the importance of non-opioid solutions like ActiPatch and RecoveryRx.
American Society of Anesthesiologists (ASA): The ASA’s stance on opioid addiction and their support for non-opioid pain management strategies helped in evaluating the potential benefits of the NOPAIN Act for companies like Bioelectronics Corporation.
________________________________________________________
Accelerated recovery of post-operative dental implant patients using drug-free RecoveryRx.
Read the paper here:
https://lnkd.in/daQ4GRa
#painrelief #neuromodulation #fdacleared #drugfree #clinicallyproven #painmanagement #oralsurgery #dentalimplants #postsurgical
https://www.linkedin.com/posts/bioelectronics-corporation_painrelief-neuromodulation-fdacleared-activity-6778677760979152896-XQZ1
___________________________________________________________________
CA OrthoAlliance
Solutions for Optimal Patient Outcomes
RecoverRX
https://orthoalliance.com/solutions-for-optimal-patient-outcomes/
_______________________________________________________________
BioElectronics Chairman Updates Investors
Thu, February 15, 2024 at 9:00 AM EST
https://finance.yahoo.com/news/bioelectronics-chairman-updates-investors-140000529.html
______________________________________________________________
Voices for Non-Opioid Choices Coalition Applauds Introduction of Alternatives to PAIN Act in Senate
https://www.prnewswire.com/news-releases/voices-for-non-opioid-choices-coalition-applauds-introduction-of-alternatives-to-pain-act-in-senate-302076547.html
____________________________________________________________
CHEMIST4u ( UK )
ActiPatch Muscle and Joint Pain Therapy Devices
https://www.chemist-4-u.com/brands/actipatch?fbclid=IwAR21Sy7YpQYVw-otDE2ah9aPf-DNslt0jUw4xJMFcKxAXRyo_JkWNQ7TcYI
____________________________________________
ActiPatch is the drug-free solution for pain. It interrupts abnormal pain signaling in the nerves. You won't feel anything but relief. $$$ BACK GUARANTEE USA:
http://actipatch.com 📷
#painmanagement #painrelief #clinicallyproven #FDAcleared #backpainrelief #NeckPainRelief
No More Dangerous, Addictive or Expensive Drugs.
https://twitter.com/ActiPatch/status/1752421581769363689?s=20
___________________________________________________________________
ActiPatch®
@ActiPatch
ActiPatch reaches deep into the painful area to provide real relief at the source. Can be used 24/7. You won't feel anything but PAIN RELIEF.
$$$ BACK GUARANTEE OFFER USA:
http://actipatch.com 📷 #neckpainrelief #techneckrelief #painrelief #neckarthritisrelief #neckpain
https://twitter.com/ActiPatch/status/1745131740358729994?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1745131740358729994%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
ITS coming to BIEL $$$$$$$$$$$$$$$$$$$!!!!!!!!!!!!!!!!!!!!!!!!
11/20/2023
Washington State poised to extend coverage for SCS
https://www.neuromodulation.org/news/washington-state-poised-to-extend-coverage-for-scs
________________________________________________________________
ActiPatch SA
February, 6 at 1:35 Am
Struggling with chronic pain? 🤕 ActiPatch® pain-relief device is clinically proven to relieve muscle and joint pain!¹?³
✅ Ideal for arthritis, back pain, knee pain, fibromyalgia, and more.²
🔍 Targeted, long-lasting pain relief in just 2-3 hours.¹
🔋 Lasts up to 720 hours for continuous comfort.
🚀 Small & lightweight.¹ Say goodbye to bulky equipment!
Get back to feeling your best with ActiPatch®, available at Dis-Chem Pharmacies, Clicks and leading pharmacies nationwide.
#ActiPatch #DrugFree #PainRelief #PainManagement #ChronicPainManagement #JointPainRelief #SportsInjuryRelief #BackPainRelief #KneePainRelief #ArthritisPainRelief #chronicpainrelief
https://www.facebook.com/watch/?v=1124676815379216
__________________________________________________________________
NANS Advocacy Results in HCSC Adding Closed-Loop Spinal Cord Stimulation to Coverage!!
https://www.neuromodulation.org/news/closed-loop-04172023
_______________________________________________________________
ActiPatch®
@ActiPatch
Get the sleep you deserve with relief from ActiPatch! ActiPatch doesn't just put a band-aid on pain. It dives deep with its Pulsed Shortwave Therapy & takes on pain at its root for sustained relief! Order at
http://actipatch.com FREE SHIPPING. #painmanagement #painfreesleep
https://twitter.com/ActiPatch/status/1737209416749887575?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1737209416749887575%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
___________________________________________________________
Chronic Pain, Fibromyalgia and Plantar Fasciitis Help --- ACTIPATCH!!!
https://www.facebook.com/groups/1795257327156301/?multi_permalinks=7709195185762456
_____________________________________________________________
SAI has Registered with FDA to Sell ActiPatch in USA and Canada for 2024
Establishment Registration and Device Listing
Establishment Name ....................... Reg number ..Current Reg Yr
AIRWAY SURGICAL APPL .CANADA 9611956 ...........2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain / Repackager/Relabeler
SURGICAL APPL INDUSTRIES , INC. USA 1511629 2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler
KT Health, LLC ......................... UT/USA 3007282994 2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
(Airway Surgical is SAI's Canadian branch)
_________________________________________________________
PEMF Alzheimer’s Treatment Pilot Underway at Hackensack University Medical Center
https://www.hackensackmeridianhealth.org/en/info/geriatrics/evoke-trial
---------------------------------------------------------------------------------------
ActiPatch
Part of STADA MENA participation at Manama Heath Congress and Expo at Bahrain
Thanks team for your efforts. Ahmed El-Barbary, Sherif Al-Kady , MBA, Diksha Ahuja, Mohamed Hosny, Abdullah Hassan, Raghdaa Badr, Mohamed Taher, Mohamed Abassi
#stada #manamahealth #caringforpeopleshealth
STADA MENA
https://www.manamahealth.com/
----------------------------------------------------------------------------------------
BioElectronics Corporation’s Post
View organization page for BioElectronics Corporation
BioElectronics Corporation
3,331 followers
Both NSAID therapy and neuromodulation therapy using PSWT resulted in statistically and clinically important reductions in pain level and improvement in functionality associated with cervical osteoarthritis, when used for 4 weeks. However, the PSWT intervention demonstrated superior improvements in all outcome measures when compared to the etoricoxib therapy arm, including patient satisfaction rating and decreased use of rescue pain medication. These results suggest that neuromodulation using PSWT may be a superior pain treatment option, when compared to COX-2 NSAIDS for neck osteoarthritis, and as well, represents a non-invasive, non-pharmacologic treatment option.
Product samples are available to licensed medical care providers in the USA. Request via email - info[ @newbie00
https://www.linkedin.com/posts/bioelectronics-corporation_pulsed-shortwave-therapy-in-cervical-osteoarthritis-activity-7138985310968795136-SRFJ
https://link.springer.com/article/10.1007/s42399-020-00652-y
---------------------------------------------------------------------------------------------------
New product added
https://actipatch.com/buy-1
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------------
Top5-USA.co
Top 5 Actipatch In The US
https://www.top5-usa.com/actipatch
------------------------------------------------------------------------------------------------------
RecoveryRX
BOSTON ORTHOPEDIC & RESPIRATORY EQUIPMENT, LLC.
https://www.bostonorthoresp.com/214-4_p_10155.html?referrer=rss
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-----------------------------------------------------------------------------------------------------------
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
Top 50 Innovative Businesses: BioElectronics Corporation, Clym Environmental Services and Cornerstone Genomics
https://www.discoverfrederickmd.com/news/top-50-innovative-businesses-bioelectronics-corporation-clym-environmental-services-and-cornerstone-genomics
" RecoveryRx repairs and regenerates damaged cells by reducing pain and inflammation and accelerating blood flow. Whereas, TENS is only blocking pain signals and has no healing effect. The major difference between the two is that a TENS unit is a short term solution that “turns off” the pain signal but CANNOT perform the function of repairing damaged tissue like RecoveryRx. "
https://www.linkedin.com/posts/lauren-jarman-380a801a9_clinicallyproven-fdacleared-noninvasive-activity-7051200138563735553-Q9Zs
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------
Watch till the end!
https://www.instagram.com/reel/Cvq8j0bILP4/?igshid=MzRlODBiNWFlZA==
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
---------------------------------------------------------------------------------------------
7 anti-aging benefits of PEMF therapy
https://www.outlookindia.com/business-spotlight/anti-aging-benefits-of-pemf-therapy-news-259187;;
"Literally, there are so many benefits to a regular PEMF therapy session. Research by NASA and other bodies has found that PEMF therapy can deliver the following results:
Better circulation
Pain reduction
Improved muscle relaxation and performance
Decreased inflammation and swelling
Improved oxygenation in tissue
Enhanced cellular repair and recovery
Improved immune system
Better sleep "
https://higherdose.com/blogs/news/8-benefits-of-pemf-therapy?psafe_param=1&tw_source=google&tw_adid=634407957086&tw_campaign=18892036948&gad=1&gclid=CjwKCAjw44mlBhAQEiwAqP3eVqY1HlussPIpcLNFP0O10gqhWUrMI0VdqtspfI3FlKHqC0HkjB_OkBoCc08QAvD_BwE
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------
INTRODUCING
RecoveryRx Veterinary
Drug-Free Pain Relief Device
For Indoor and Outdoor Pets
https://rrxvet.carrd.co/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
----------------------------------------------------------------------------------------------------------
Once, pay ATTENTION Everyone -- NOT if, IMO, NHL, NFL, NBA, WBA, MLB, PGA, Lacross, etc...... adopts Actipatch as a must protocol, after all those HITS, CHECKS, TRIPS, LIGAMENT PULLS/RIPS, etc.......Possibilities are ENDLESS !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
---------------------------------------------------------------------------------------------
ATTENTION all the Respected, Smart, Intelligent Investors !!!!!!! Do your OWN, INTELLIGENT, THOROUGH DD, without ANY influence from KNOWN PAID BASHERS / LIARS / MANIPULAYOTS / MISINFORMERS !!!!!!!!! Make sure, if you decide to invest ( and to decide you MUST !! ) :
#1 -- Don't put all the money you are willing to invest in one basket ( buy only one stock ), be diverse......VERY IMPORTANT -- Do your OWN, INTELLIGENT DD !!!!!!!!!!!!!!!!
#2 -- If you decide/willing to buy BIEL shares, know, that this is a HIGH RETURN / HIGH LOSS RISK ratio, but the MIRACLE PRODUCT ( ACTIPATCH ) is the key !!!!
#3 -- if you decide/willing to buy BIEL shares, invest only as much as you are willing to loose, without being hurt, FINANCIALLY !!!!!!!!!!!!!!!!!
Good luck to all !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$
Come on Icahn, please explain how cash flow is important to a company.
That all you got? Lame.
I was not talking to you.
What's my point?
This thing will blow a gasket like there is no tomorrow
Don't listen to decrepit clowns they don't matter.
GO BIEL!!
It's not a press release
Followers
|
1073
|
Posters
|
|
Posts (Today)
|
43
|
Posts (Total)
|
333960
|
Created
|
05/18/05
|
Type
|
Free
|
Moderators misanthrope Capsule JustGoDeep toohot JNdouble1 gimmee greenbacks |
PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) ("the Company") back onto the "Stock Day" podcast. Andy spoke with Everett about their progress in the US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch(R) Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx(R) Devices for chronic and post-operative wound care; Allay(R) Menstrual Pain Therapy. For more information, please visit http://www.bielcorp.com/
The Company is currently pursuing multiple US partnership opportunities that are partially contingent on additional FDA clearance for the treatment of musculoskeletal pain, back pain, knee pain, muscle, hip, carpal tunnel, etc. Whelan said,"Patience is key throughout this process. It's going as well as it can." Additionally, the Company anticipates solidifying deals with two new major distributors in the Asian and Eastern European markets.
The Company's product development and regulatory clearances are going well. Now, with pre-submission clearance, the 510(k) relief of musculoskeletal pain market clearance application will be filed by the end of June.
The US FDA has recently implemented an Innovation Program seeking "Breakthrough Devices" to Prevent and Treat Opioid Use Disorder. Opioids are routinely used for post-operative pain. Our United Kingdom ActiPatch User Registry accounts that 71% of opioid customers report a moderate (50%) to complete (100%) elimination in opioid medication use. The Company plans to submit its post-operative pain relief market clearance application into this program. The FDA's assistance, participation, and approval will provide credence and accelerate product market acceptance.
The Company has begun shipments of its new single box kinesiology tape product to be used for back, knee, hip, and muscles and joints in lieu of the back wrap, knee wrap and muscle and joint adhesives. The kinesiology tape is easier to use, reduces product costs, and retail shelf space requirements.
The Company is transitioning its United Kingdom over-the-counter sales and marketing from the front of the store to behind the counter to expand product availability from a few stores to all 14,000 pharmacies. Most pharmacies obtain daily product deliveries and most people in the UK qualify for free prescriptions.
Whelan is confident in the direction the Company is moving, and cites the unique nature of their products as a factor that helps the Company stand out in the global medical electronics industry. Whelan then said, "This is one busy little Company."
"Stock Day" host Everett Jolly stands by his assessment from his April interview with the company that the stock is very undervalued. BioElectronics Corporation trades on the OTC Pink market under the ticker symbol BIEL. Shares are currently selling at 0.0037, up over 100% since April.
For more details about the Company's recent FDA meetings, potential partnership opportunities, and attempts to combat the ongoing opioid crisis, follow the link below to hear the full interview.
https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-3/ ;
About BioElectronics Corporation
BioElectronics develops and manufactures unique nonprescription affordable neuromodulation medical devices. The Company's technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation for many neurological disorders, and specifically chronic pain. Central sensitization is difficult, if not impossible, to address through pharmacotherapy without having a detrimental impact on normal physiologic function. Moreover, pharmacological and masking therapies (creams, heat patches, TENS etc.) have limited effectiveness for chronic pain due to their transient nature. BioElectronics' electromagnetic stimulation therapy has the distinct advantage of being safe, affordable, long lasting, and effective pain relief.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK […]
FREDERICK, MD, May 29, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com reports that it has cancelled today’s scheduled US Food and Drug Administration meeting. “The FDA’s response to our questions, suggestions, and instructions are more than adequate for us to proceed with filing of the formal 510(k) Market Clearance Application,” stated Ian […]
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what […]
FREDERICK, MD, May 02, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two meetings have been scheduled with the US Food and Drug Administration (FDA) to seek expanded over-the-counter (OTC) clearances for their drug-free, wearable medical devices. The first meeting will take place on May 9th, 2018 to […]
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) — Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) (“the Company”), return to the “Stock Day” podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product […]
FREDERICK, MD, March 19, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. Currently there are 700,000 total knee replacement surgeries in the US alone and are projected to grow 673% to 3.5 million procedures per […]
PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) — The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world […]
FREDERICK, MD, Jan. 09, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today that CARE Pharmacies has committed to introducing ActiPatch, Musculoskeletal Pain Therapy medical device to its patients. “With the current opioid crisis here in the United States, as pharmacists, we […]
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half […]
FREDERICK, MD, Dec. 12, 2017 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain […]
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (BIEL) , www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what regulatory pathway should be followed to get market clearance. The focus of the May 9 pre-submission meeting was in discussing the FDA’s feedback on the clinical outcomes and statistical techniques used in reporting the back-pain study.
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
The company was represented by their clinical R&D team comprising: Sree Koneru, Ph.D., VP Product Development, Ian Rawe, Director Clinical Research of BioElectronics (BIEL), Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D. Professor Duke University. Dr. Koneru, who led the discussion, expressed confidence in the FDA’s constructive feedback. “We are pleased that the FDA viewed our data and statistical methods favorably. They have provided guidance on how to combine the back-pain study results, along with our previously cleared 510(k), into a single 510(k) submission for obtaining expedited expanded market clearance.”, he said.
An additional pre-submission meeting is scheduled with the FDA on May 29th, 2018 to seek expanded indications in a separate application for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
BioElectronics VP of Sales Discusses Pre & Post-operative Pain Relief Surgical Program in "Stock Day" Interview
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) ("the Company"), return to the "Stock Day" podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product opportunity from the recent National Health Service payment approval for its ActiPatch® medical device.
BioElectronics is with B. Braun Medical, Ltd.UK to initiate the "Total Pathways Program" program into B. Braun's 26 geographic markets. The program is for pre-habilitation (treatment that happens prior to surgery) and post-operative recovery. This new program will benefit the majority of the 160,000 UK annual knee, hip, or joint replacements patients. According to Keith, BioElectronics is not just trying establishing a brand, but "to establish the process to a standardize care for pre and post-operative pain."
The company is immensely proud of their team for getting their concept through to the National Health Service (NHS) in the UK. In addition to successes here, the company is hoping to utilize their overseas success by applying data to their US-based efforts.
There are some great potential partnerships currently being discussed at BioElectronics, with the closing of a significant deal just on the horizon.
BioElectronics Corp is approaching their upcoming FDA meetings with confidence. "We have the data to make a very strong case for both broader musculoskeletal and post-operative pain relief indications," said Nalepka. "It's an exciting time for the company, and a really cool little product."
For more details on the Total Pathways Program, news about a partnerships, and information about the company's upcoming meetings with the FDA, follow the link below to the full interview.
https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel-3/ ;
About BioElectronics
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
Safe Harbor Statement
Certain statements contained herein are "forward-looking statements," (as defined in the Private Securities Litigation Reform Act of 1995). BioElectronics Corp. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. BioElectronics Corp. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network "Stock Day" Podcast. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Contact Information
Uptick Newswire LLC
Everett Jolly, CEO/Founder
602-441-3474
10000 N. 31st Avenue C307 Phoenix, AZ 85051
info@upticknewswire.com
www.upticknewswire.com
Release #:812-170554-rl-1141231: |
BioElectronics Up-Date |
Dear Fellow Shareholders, This letter is to report on our recent progress in marketing and product development. We have established the following:
We are continuing to solicit new international and domestic sales and marketing partners for distribution and licensing, while strengthening our relationship with existing partners. To aid in this effort we have engaged an accomplished sales and marketing pharmaceutical consultant to assist in introduction and negotiations of sales and marketing partnerships. US Market Clearance ActiPatch®, Musculoskeletal Pain Therapy We are in the process of expanding the US market clearance from relief of osteoarthritis of the knee pain and plantar fasciitis. Our goal is to obtain general clearance for musculoskeletal pain. To achieve this, we have submitted a chronic back pain clinical study to the US FDA as a formal Pre-Sub. The initial meeting with the FDA is tentatively scheduled for May 9th. Prior guidance from the FDA indicated that a third clinical study was required before expanding the current market indications to cover all musculoskeletal pain. We are hopeful that the process will be completed rapidly, however we will not have a good estimate of this market clearance date until the completion of the May 9th meeting. Postoperative Recovery and Pain We have submitted a formal Pre-Sub to the US FDA for guidance in obtaining market clearance for the palliative treatment of postoperative pain and edema. The application is supported by postoperative clinical studies on breast augmentation and caesarean section. Marketing Expansion We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line. Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:
The ActiPatch registry studies report that people buy the device because it is effective, drug-free, has no harmful side effects and overall improves quality of life. We are continually working to solve existing minor issues with the use of ActiPatch. To improve the product, we are introducing custom-design kinesiology tape strips to attach the device to the body. Aside from improving user comfort, this allows us to promote a single multi-purpose box with the added benefit of reducing retail shelf space. We believe this will then allow us to sell the 7-day trial devices from pharmacy shelves. B. Braun UK This is an important development for BioElectronics. B Braun has been using RecoveryRx to improve recovery following joint replacement for many years, although in limited surgeries. However, new advances in day surgery for joint replacement have expanded our opportunity. B. Braun has recently completed a pilot program in the UK evaluating day for joint replacement. The United Kingdom's Group day surgery program for knee and hip replacement patients and is now being implemented on a national basis. Currently there are 80,000 procedures per year involving B Braun. The "fast-track" same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a special wireless technology tablet. Upon hospital discharge, each patient will be given an ActiPatch medical device and a prescription for 6 additional devices to help accelerate recovery and mitigate the postoperative pain. A similar program is in development for spinal surgeries. On an international level, B. Braun's 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services. It is anticipated that B. Braun's German Group will roll out the same day hip and knee replacement program in the next few months.
Smart Insole – Heel Pain Relief We have redesigned the Smart™ Insole plantar fasciitis insole to enhance user comfort. We are awaiting a written License and Supply Agreement for the product. Clinical Research to Expand Market Clearance and Acceptance Allay®, Menstrual Pain Therapy 28% of women are in the menstrual phase of life and 60% have moderate to severe menstrual pain, or 17% of women. Previously our medical devices were classified as high risk class III by the US FDA. While our existing pilot clinical study for menstrual pain reported exceptional results for menstrual pain, to publish a clinical study and obtain US market clearance, we are collaborating with the University Hospital at Birmingham, UK. The researchers here are world renowned thought leaders in women's health and are conducting a double-blind randomized controlled trial to evaluate the efficacy of ActiPatch in reducing menstrual pain (clinicaltrials.gov listing NCT03394547). You can view the existing clinical evidence and our commercials at https://www.myallay.com/ Prevention of Episodic Migraines Headaches Migraines affect 36 million men, women and children in the United States alone. The facts are:
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception; since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attack. There is pilot data that ActiPatch can help mitigate this sensitization, so a study has been completed to determine the efficacy of ActiPatch in preventing chronic, episodic migraines. The data from the study will be analysed in the next few weeks. We believe this data will allow us to work towards developing a product as a migraine therapy and allowing us to obtain market clearance. Postoperative Recovery and Pain Working with our distributor in Lebanon we are conducting a double blind placebo randomized controlled trial on total knee replacement (clinicaltrial.gov NCT03395444). Through our long standing association with B. Braun UK, RecoveryRx has been determined to be a valuable aid in joint replacement surgery. This clinical study will allow us to gain worldwide recognition and allow for expanded marketing and acceptance of the RecoveryRx as a standard of post-operative care following joint replacement. Interstitial Cystitis (Overactive Bladder and Pelvic Pain) This study is a University of Texas, McGovern Medical School sponsored double blind randomized controlled trial. The goal is to determine how well the ActiPatch therapy works in treating patients with interstitial cystitis, bladder pain syndrome and overactive bladder. Interstitial cystitis and bladder pain syndrome are chronic bladder health conditions that greatly affect quality of life. These conditions create intermittent feelings of pain and pressure in the bladder area. The study is expected to recruit 60 women who are urology patients of the University's hospital. At least 35 million Americans have overactive bladder. Lower urinary tract symptoms, urgency, and pelvic pain are common complaints to urologists and primary care physicians. Additional Bioelectronic Product Opportunities As we develop the organizational structure we envision additional opportunities in chronic wounds, neuropathy, hypertensive therapy, etc. Most importantly future growth is not dependent on large capital outlays for research and development. Immediate Sales Growth We anticipate imminent solid sales growth from the following programs:
Thank you for your support. Sincerely,
______________________ |
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK Group to improve care and reduce the UK healthcare cost of its 160,000 annual hip and knee replacement procedures.
The “fast-track” same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a specialized wireless tablet. Each patient will be given an ActiPatch medical device and a prescription for 6 additional ActiPatch devices. A similar program is being implemented for spinal surgeries.
Phil Cleary, Senior Product Group Manager, stated that “our TOTAL Pathway program enhances our commitment to patient safety, post-operative care, as well as significantly reducing healthcare costs and hospital stays.” Treating post-surgical pain requires a multifaceted approach. In trials, ActiPatch was well received and produced positive outcomes. We look forward to making this program a success, in the UK and other countries where B. Braun operates.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
About B. Braun Medical Ltd
B. Braun Medical Ltd, UK, https://www.bbraun.co.uk/ is a member of the B. Braun Group, https://www.bbraun.com/en.html one of the world´s leading healthcare companies. On an international level, B. Braun’s 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services.
Keep in mind partners are happening and licensed ones at that.
The back study will not go in as a new submission, it is included in the knee and ankle submission so this will happen quicker than most would believe. Well actually the back study will be added to the prior submission, I don't want to confuse you
Watch how huge the Co-Branding gets. How many names besides Pain Gear?
Increasing shareholder value=7 components of shareholder value.
• Revenue
• Operating Margin
• Cash Tax Rate
• Incremental Capital Expenditure
• Investment in Working Capital
• Cost of Capital
• Competitive Advantage Period
Within the next 120 days BIEL will have in place-
Full body clearance minus the Migraine, anticipated clearance at a later date based upon the fact that this is a preventative study and the patients must have signs of a migraine coming, this study is a little more complicated.
Licensed partners (Major)
Equity partners
At least 2 huge retail chains
Let’s add on a few more distributors. Why not? Lol
NHS-first week of April, keep in mind not the only week, this is lifetime!
There will be other EU States that will duplicate the NHS and this will be coupled with licenses being sold to partners. What price, how much in royalties will soon be determined.
The August financials will and should be the strength of evidence that a certain person has established a supply chain that will be second to none.
I should mention that sales makeup only one component of the revenue stream, this is where my opinion may differ from the good posters on the BIEL board.
Revenue is the total amount taken in by a business in a set period of time.
This can include royalties, license fees and equity from partners and sales.
BIEL cannot have millions in sales without including the other revenue streams mentioned above.
My revenue forecast including sales may be different than others.
Great rewards will follow in due time. Waiting on the FDA protocol. Which means pre-submission. Guidance, rules and timing will be part of the protocol.(Looks like May-June clearance.)
Migraine clinical results will still be the huge one for the FDA protocol.(August-September clearance on positive results.)
NHS is the first of many EU States getting on board. Pretty good health systems across the pond. Sweden next!
The back pain study will obtain US FDA clearance for relief of musculoskeletal pain. Migraine headaches are not musculoskeletal. Migraines and musculoskeletal pain are both neurological disorders. Two FDA clearances!!!!!!!!!!!!!
SEC-much ado about nothing!
Partners-much ado about something!
12/7/2017 - Try and Tell US Launch, gets a 7 Day ActiPatch to US residents for shipping and handling costs of $4.95
12/7/17 - BIEL closes a deal with ANDA for National Distribution, ANDA has 60,000 commercial customers and is owned by TEVA Pharma, TEVA has extensive business dealings with the NHS
1/4/2018 - ActiPatch gains admission to the UK NHS Drug Tariff as a covered medical device, The NHS is the largest single healthcare delivery organization in the world
1/9/2018 - CARE Pharmacies will be handling the ActiPatch, CARE is an organization of 90 pharmacies in 17 states, CARE will be educating patients on the benefits of drug-free pain relief through Pain Consultations
1/16/2018 - Allay Menstrual Clinical Study is fully enrolled, taking place at the prestigious Birmingham Women's Hospital,an NHS Foundation Hospital
1/22/2018 - BIEL signs deal with Performance Health, 120 outside sales reps, 40 inside reps, KN interview
1/22/2018 - BIEL signs deal with MundiPharma in Australia and 8 other countries, Mundi is associated with Purdue Pharma, KN interview
1/22/2018 - Back Pain Study is complete, BIEL has dialogue ongoing with FDA for submission of Study to expand ActiPatch indications, KN interview
1/22/2018 - Migraine Study will get the full attention of staff now that the Back Study has been completed
1/22/2018 - BIEL in talks with Walmart
1/22/2018 - Meeting scheduled with CVS
This is the last 2 months of activity for BIEL. Any other OTC company would be dancing in the Street if they had accomplished this much in the last year.
The NHS Approval has opened new doors for BIEL and will continue to do so for many years.
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government-funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
References
1 NHS, "NHS Choices," January 2018. [Online].http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
Available: https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pai....
2 Arthritis Research UK, "Muscloskeletal Matters," Keele University, 2009
ActiPatch Cost Assessment Study Used By UK's NHS
http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
This improvement translated into reduced utilization of healthcare services, leading to a 36.8% reduction in health care costs to the NHS over a 3-month period, even after accounting for the cost of the ActiPatch device
Conclusion
Utilizing ActiPatch® as a chronic pain therapy treatment improves patient quality of life, while reducing the economic burden to the NHS.
"Almost half the adult population is living with chronic pain," the Daily Mail reports. A major new review suggests that around 28 million adults in the UK are affected by some type of chronic pain (pain that lasts for more than three months). Read More Link
https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pain/
February 06, 2017 09:05 ET
FREDERICK, MD--(Marketwired - Feb 6, 2017) - BioElectronics Corporation (OTC PINK: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
How to Order an ActiPatch®?
Visit tryactipatch.com to place your order for the ActiPatch® today.
www.tryactipatch.com
BioElectronics Corporation
301-874-4980
info@bielcorp.com
4539 Metropolitan Court
Frederick, MD 21704
ActiPatch Healthcare Utilization Study Link
http://www.harmonyhealth.se/wp-content/uploads/2017/10/ActiPatchHealthcareCostStudy.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |